Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in pr
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of
Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.
A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational
ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t